Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rust, D. M.
Right arrow Articles by Soignet, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rust, D. M.
Right arrow Articles by Soignet, S. L.
The Oncologist, Vol. 6, Suppl 2, 29-32, April 2001
© 2001 AlphaMed Press


SUPPLEMENT

Risk/Benefit Profile of Arsenic Trioxide

Deborah M. Rusta, Steven L. Soignetb

a Acute Care Nurse Practitioner Program (Oncology Subspecialty), School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; b Memorial Sloan-Kettering Cancer Center and Department of Medicine, and the Joan and Sanford Weill Medical College of Cornell University, New York, New York, USA

Correspondence: Steven L. Soignet, M.D., Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021-6007, USA. Telephone: 212-639-8984; Fax: 212-717-3172; e-mail: soignets{at}mskcc.org

Approximately 20%-30% of patients with acute promyelocytic leukemia (APL) who are treated with the current standard all-trans retinoic acid and anthracycline-based chemotherapy regimen suffer relapse. In the mid-1990s, studies from China reported the effective use of arsenic trioxide in achieving complete remission in patients with APL. In the United States, a multicenter trial of this agent in 40 patients with relapsed APL following conventional therapy confirmed the positive safety and efficacy outcomes of a smaller 12-patient pilot study. Common adverse events were hyperleukocytosis, APL differentiation syndrome, prolonged QT interval on electrocardiogram, skin rash, and hyperglycemia.

Key Words. Arsenic trioxide • Acute promyelocytic leukemia • All-trans retinoic acid • APL differentiation syndrome • Hyperleukocytosis • QT interval




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
A. M. Tsimberidou, L. H. Camacho, S. Verstovsek, C. Ng, D. S. Hong, C. K. Uehara, C. Gutierrez, S. Daring, J. Stevens, P. B. Komarnitsky, et al.
A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors
Clin. Cancer Res., July 15, 2009; 15(14): 4769 - 4776.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Phatak, F. Dai, M. Butler, M.P. Nandakumar, P. L. Gutierrez, M. J. Edelman, H. Hendriks, and A. M. Burger
KML001 Cytotoxic Activity Is Associated with Its Binding to Telomeric Sequences and Telomere Erosion in Prostate Cancer Cells
Clin. Cancer Res., July 15, 2008; 14(14): 4593 - 4602.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H.-Y. Jiang, L. Jiang, and R. C. Wek
The Eukaryotic Initiation Factor-2 Kinase Pathway Facilitates Differential GADD45a Expression in Response to Environmental Stress
J. Biol. Chem., February 9, 2007; 282(6): 3755 - 3765.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. A. Rich, R. C. Shepard, and S. T. Mosley
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. Drolet, C. Simard, and D. M. Roden
Unusual Effects of a QT-Prolonging Drug, Arsenic Trioxide, on Cardiac Potassium Currents
Circulation, January 6, 2004; 109(1): 26 - 29.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Pentheroudakis and N. Pavlidis
Immunomodulation in colorectal cancer: disappointment or promise?
Ann. Onc., March 1, 2003; 14(3): 349 - 351.
[Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.
Advertisement